Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

LNSR

LENSAR Inc

Apr 13 • 01:23PM ET

5.73

+0.03 0.53 %

Healthcare • Medical Devices • USA • NASD

Peers: STAA ICUI IART CERS ATEC HAE MLAB CUTR LMAT

| Held by: VTI IWM VXF VTWO IWO DFMC IWC DFAS VTWG GSSC

Index	RUT	P/E	-	EPS (ttm)	-2.90	Insider Own	21.38%	Shs Outstand	11.99M	Perf Week	-2.72%
Market Cap	69.31M	Forward P/E	-	EPS next Y	-0.33	Insider Trans	0.00%	Shs Float	9.51M	Perf Month	-50.92%
Enterprise Value	67.84M	PEG	-	EPS next Q	0.18	Inst Own	48.45%	Short Float	10.69%	Perf Quarter	-50.48%
Income	-34.28M	P/S	1.19	EPS this Y	89.40%	Inst Trans	-0.48%	Short Ratio	9.79	Perf Half Y	-52.21%
Sales	58.44M	P/B	-	EPS next Y	-9.96%	ROA	-49.78%	Short Interest	1.02M	Perf YTD	-50.73%
Book/sh	-2.17	P/C	3.85	EPS next 5Y	-	ROE	-1069.41%	52W High	14.31 -59.96%	Perf Year	-57.52%
Cash/sh	1.49	P/FCF	-	EPS past 3/5Y	-13.51% -9.65%	ROIC	-	52W Low	5.33 7.50%	Perf 3Y	124.71%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	18.23% 17.24%	Gross Margin	44.84%	Volatility	5.43% 8.49%	Perf 5Y	-19.18%
Dividend TTM	-	EV/Sales	1.16	EPS Y/Y TTM	-6.71%	Oper. Margin	-42.06%	ATR (14)	0.48	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.62	Sales Y/Y TTM	9.24%	Profit Margin	-58.66%	RSI (14)	27.41	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.15	EPS Q/Q	92.49%	SMA20	-6.33%	Beta	1.00	Target Price	8.50
Payout	-	Debt/Eq	-	Sales Q/Q	-4.22%	SMA50	-40.49%	Rel Volume	0.46	Prev Close	5.70
Employees	150	LT Debt/Eq	-	Earnings	Mar 31 BMO	SMA200	-49.95%	Avg Volume	103.81K	Price	5.73
IPO	Oct 02, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-80.72% -37.63%	Trades		Volume	29,324	Change	0.53%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-01-26	Upgrade	Lake Street	Hold → Buy	$10
Mar-18-26	Upgrade	BTIG Research	Neutral → Buy	$10
Feb-24-21	Initiated	SVB Leerink	Outperform	$20

Apr-03-26 09:00PM	LENSAR Inc (LNSR) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges (GuruFocus.com)
Apr-01-26 08:30AM	LENSAR, Inc. Q4 2025 Earnings Call Summary (Moby)
Mar-31-26 06:00AM	LENSAR Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update (GlobeNewswire)
Mar-30-26 09:18AM	Earnings To Watch: LENSAR Inc (LNSR) Reports Q4 2025 Result (GuruFocus.com)
Mar-17-26 09:33AM	BYND And LNSR Set The Tone Tuesday (GuruFocus.com) -32.85%
06:57AM	Loading…
06:57AM	Alcon abandons effort to purchase LENSAR after FTC scrutiny (MedTech Dive)
Mar-16-26 04:57PM	Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement (Business Wire)
04:30PM	LENSAR Announces Termination of Merger Agreement with Alcon Research, LLC (GlobeNewswire)
Feb-25-26 05:00PM	LENSAR Provides Update on Pending Acquisition by Alcon (GlobeNewswire)
Nov-06-25 07:00AM	LENSAR Reports Third Quarter 2025 Results and Provides Business Update (GlobeNewswire) -8.63%
Sep-02-25 04:01PM	LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-07-25 07:00AM	LENSAR Reports Second Quarter 2025 Results and Provides Business Update (GlobeNewswire)
Jul-01-25 04:01PM	LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-25 04:01PM	LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-08-25 07:00AM	LENSAR Reports First Quarter 2025 Results and Provides Business Update (GlobeNewswire)
09:20AM	Loading…
Apr-24-25 09:20AM	LENSAR: It Is All About The Contingent Value Right Now (Seeking Alpha)
Apr-10-25 01:59PM	Alcon: A Clear Vision, But Fully Valued (Seeking Alpha)
08:35AM	Is LENSAR (LNSR) a Deeply Undervalued Stock? (Insider Monkey)
Mar-25-25 09:00AM	Morning Movers: 23andMe plummets after Chapter 11 proceedings and CEO exit (TipRanks)
08:35AM	ALC Stock Rises Following the Merger Agreement With LENSAR (Zacks)
Mar-24-25 08:00AM	Alcon Agrees to Acquire LENSAR, Inc. (GlobeNewswire)
Mar-03-25 07:03PM	LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-28-25 02:17AM	LENSAR Inc (LNSR) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... (GuruFocus.com) +19.60%
Feb-27-25 07:00AM	LENSAR Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update (GlobeNewswire) +14.78%
Feb-26-25 08:18AM	Earnings To Watch: LENSAR Inc (LNSR) Reports Q4 2024 Result (GuruFocus.com)
Feb-19-25 12:00PM	LENSAR to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 27, 2025 (GlobeNewswire)
Feb-03-25 07:33PM	LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.63%
Jan-02-25 06:08PM	LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-09-24 04:01PM	LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-26-24 08:00AM	LENSAR to Participate in the BTIG 4th Annual Ophthalmology Day (GlobeNewswire)
02:14AM	Loading…
Nov-08-24 02:14AM	LENSAR Inc (LNSR) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Expansion (GuruFocus.com) +7.42%
Nov-07-24 07:00AM	LENSAR Reports Third Quarter 2024 Results and Provides Business Update (GlobeNewswire) +17.24%
Nov-06-24 07:53AM	LENSAR Inc (LNSR) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-01-24 06:32PM	LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.28% +8.92%
Oct-31-24 07:00AM	LENSAR to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024 (GlobeNewswire)
Oct-09-24 08:15AM	Lensar announces more than 1M procedures completed with cataract laser systems (TipRanks)
Oct-08-24 08:00AM	One Millionth Procedure Completed Using LENSAR's Cataract Laser Systems (GlobeNewswire) +6.11%
Oct-01-24 06:25PM	LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-04-24 04:01PM	LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:00AM	LENSAR to Participate in Two Upcoming Investor Conferences (Business Wire)
Aug-08-24 07:00AM	LENSAR Reports Second Quarter 2024 Results and Provides Business Update (Business Wire) -9.93%
Aug-07-24 07:00AM	LENSAR Announces Certification for the ALLY Adaptive Cataract Treatment System in the European Union (Business Wire) -7.90%
Aug-01-24 06:42PM	LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
07:00AM	LENSAR to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 (Business Wire)
Jul-05-24 10:00AM	3 Under-$10 Stocks With the Potential to Make You a Millionaire (InvestorPlace)
Jul-02-24 05:50PM	LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.80%
Jun-03-24 06:34PM	LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.33%
May-23-24 08:00AM	LENSAR to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference (Business Wire)
May-13-24 11:14AM	LENSAR, Inc. (NASDAQ:LNSR) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 11:57AM	LNSR Stock Earnings: LENSAR Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +12.68%
07:00AM	LENSAR Reports First Quarter 2024 Results and Provides Business Update (Business Wire)
May-02-24 08:00AM	LENSAR to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024 (Business Wire)
May-01-24 06:38PM	LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-01-24 06:28PM	LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-05-24 09:11AM	LENSAR, Inc. (NASDAQ:LNSR) Q4 2023 Earnings Call Transcript (Insider Monkey) -10.97%
Mar-04-24 07:00AM	LENSAR Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update (Business Wire)
Mar-01-24 05:01PM	LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-26-24 08:00AM	LENSAR to Report Fourth Quarter and Full Year 2023 Financial Results on Monday, March 4, 2024 (Business Wire)
Nov-12-23 09:38AM	LENSAR, Inc. (NASDAQ:LNSR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 07:00AM	LENSAR Reports Third Quarter 2023 Results and Provides Business Update (Business Wire) +12.44%
Nov-02-23 08:03AM	LENSAR to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023 (Business Wire) +5.12%
Aug-09-23 07:00AM	LENSAR Reports Second Quarter 2023 Results and Provides Business Update (Business Wire) +12.73%
Jul-24-23 07:00AM	LENSAR® Reports Adoption of ALLY® System in Multi-Center Ophthalmology Groups (Business Wire)
May-15-23 07:00AM	LENSAR Reports First Quarter 2023 Results and Provides Business Update (Business Wire) -9.45%
May-10-23 08:00AM	LENSAR to Report First Quarter 2023 Financial Results on Monday, May 15, 2023 (Business Wire)
Mar-20-23 03:05AM	LENSAR, Inc. (NASDAQ:LNSR) Q4 2022 Earnings Call Transcript (Insider Monkey) -10.98%
Mar-16-23 07:00AM	LENSAR Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update (Business Wire)
Mar-09-23 08:00AM	LENSAR to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023 (Business Wire)
Feb-14-23 07:00AM	LENSAR Announces Preliminary Fourth Quarter and Full Year 2022 Results (Business Wire)
Nov-22-22 08:00AM	LENSAR to Present at Two Upcoming Investor Conferences (Business Wire)
Nov-09-22 07:00AM	LENSAR Reports Third Quarter 2022 Financial Results and Provides Business Update (Business Wire) -11.56%
Nov-02-22 08:00AM	LENSAR to Report Third Quarter 2022 Financial Results on Wednesday, November 9, 2022 (Business Wire)
Sep-08-22 07:00AM	LENSAR Announces Application for Certification of the ALLY Adaptive Cataract Treatment System in the EU (Business Wire)
Aug-16-22 07:00AM	First Patients Treated with LENSARs® ALLY Adaptive Cataract Treatment System (Business Wire)
Aug-08-22 07:00AM	LENSAR Reports Second Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Aug-01-22 08:00AM	LENSAR to Report Second Quarter 2022 Financial Results on Monday, August 8, 2022 (Business Wire)
Jun-13-22 07:00AM	LENSAR® Receives U.S. FDA Clearance of ALLY Adaptive Cataract Treatment System (Business Wire)
Jun-09-22 07:30AM	Shareholders in LENSAR (NASDAQ:LNSR) are in the red if they invested a year ago (Simply Wall St.)
May-09-22 07:00AM	LENSAR Reports First Quarter 2022 Financial Results and Provides Business Update (Business Wire)
May-02-22 08:00AM	LENSAR to Report First Quarter 2022 Financial Results on Monday, May 9, 2022 (Business Wire)
Apr-21-22 09:08AM	We're Not Very Worried About LENSAR's (NASDAQ:LNSR) Cash Burn Rate (Simply Wall St.)
Mar-03-22 07:00AM	LENSAR Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update (Business Wire) +6.34%
Mar-01-22 07:00AM	LENSAR Announces U.S. Food and Drug Administration Acceptance of 510(k) Submission for ALLY (Business Wire)
Feb-28-22 04:01PM	LENSAR to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 3, 2022 (Business Wire)
Feb-23-22 02:01AM	Should Now Consider Selling Your LENSAR (LNSR) Shares? (Insider Monkey)
Feb-10-22 08:00AM	LENSAR to Participate in Two Upcoming Investor Conferences (Business Wire)
Jan-04-22 08:00AM	LENSAR to Present at the H.C. Wainwright Virtual BioConnect Conference (Business Wire)
Dec-31-21 07:53AM	Shareholders in LENSAR (NASDAQ:LNSR) are in the red if they invested a year ago (Simply Wall St.)
Nov-16-21 08:00AM	LENSAR to Present at Two Upcoming Investor Conferences (Business Wire)
Nov-12-21 07:00AM	LENSAR Announces Poster Presentations at the American Academy of Ophthalmology (Business Wire)
Nov-08-21 07:00AM	LENSAR Reports Third Quarter 2021 Financial Results and Provides Business Update (Business Wire)
Nov-01-21 08:00AM	LENSAR to Report Third Quarter 2021 Financial Results on Monday, November 8, 2021 (Business Wire)
Oct-02-21 10:32AM	We Think LENSAR (NASDAQ:LNSR) Can Afford To Drive Business Growth (Simply Wall St.)
Sep-02-21 08:00AM	LENSAR to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (Business Wire)
Aug-16-21 08:00AM	LENSAR to Present at the H.C. Wainwright Ophthalmology Virtual Conference (Business Wire)
Aug-05-21 07:00AM	LENSAR Reports Second Quarter 2021 Financial Results and Provides Business Update (Business Wire)
Jul-29-21 08:00AM	LENSAR to Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021 (Business Wire)
Jul-15-21 08:00AM	LENSAR Announces In-Person Demonstrations of Its Next Generation ALLY System and Multiple Data Presentations at the American Society of Cataract and Refractive Surgery (ASCRS) 2021 Annual Meeting (Business Wire)
May-24-21 08:00AM	LENSAR to Present at the Oppenheimer MedTech, Tools, & Diagnostics Summit (Business Wire)
May-05-21 07:00AM	LENSAR Reports First Quarter 2021 Financial Results and Provides Business Update (Business Wire)

LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. Its product offers automation and customization options for astigmatism treatment planning and other steps of the refractive cataract surgery procedure. The company was founded by Scott Addyman, Randy W. Frey, and Ronald R. Krueger in 2004 and is headquartered in Orlando, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
STAAB THOMAS R II	Chief Financial Officer	Mar 19 '26	Option Exercise	2.65	5,500	14,575	175,959	Mar 19 04:45 PM

Open in Screener

HCWB

HCW Biologics Inc

Apr 13 • 01:23PM ET

0.3699

+0.0054 1.48 %

Healthcare • Biotechnology • USA • NASD

HCWB HCW Biologics Inc daily Stock Chart

Peers: LGND AUPH BYSI IVA FATE ARDX GERN CRBP TVRD CBIO

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-11.79	Insider Own	17.84%	Shs Outstand	6.73M	Perf Week	28.71%
Market Cap	2.49M	Forward P/E	-	EPS next Y	-0.55	Insider Trans	0.00%	Shs Float	5.53M	Perf Month	-33.84%
Enterprise Value	7.35M	PEG	-	EPS next Q	-0.44	Inst Own	6.78%	Short Float	2.00%	Perf Quarter	-69.68%
Income	-22.30M	P/S	49.73	EPS this Y	90.97%	Inst Trans	-23.44%	Short Ratio	0.01	Perf Half Y	-91.85%
Sales	0.05M	P/B	0.44	EPS next Y	42.71%	ROA	-81.45%	Short Interest	0.11M	Perf YTD	-61.89%
Book/sh	0.84	P/C	1.28	EPS next 5Y	64.89%	ROE	-27725.80%	52W High	17.80 -97.92%	Perf Year	-95.97%
Cash/sh	0.29	P/FCF	-	EPS past 3/5Y	13.87% -6.63%	ROIC	-806.53%	52W Low	0.25 47.96%	Perf 3Y	-99.35%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-79.94% -57.90%	Gross Margin	-1900.99%	Volatility	13.83% 22.72%	Perf 5Y	-
Dividend TTM	-	EV/Sales	146.93	EPS Y/Y TTM	62.56%	Oper. Margin	-24256.67%	ATR (14)	0.09	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.11	Sales Y/Y TTM	-97.89%	Profit Margin	-41118.00%	RSI (14)	40.72	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.11	EPS Q/Q	67.89%	SMA20	-22.78%	Beta	0.92	Target Price	2.00
Payout	-	Debt/Eq	2.47	Sales Q/Q	-93.16%	SMA50	-41.44%	Rel Volume	0.07	Prev Close	0.36
Employees	35	LT Debt/Eq	0.00	Earnings	Mar 31 AMC	SMA200	-85.98%	Avg Volume	8.22M	Price	0.37
IPO	Jul 20, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-21.43% -	Trades		Volume	374,491	Change	1.48%

Mar-31-26 05:05PM	HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results (GlobeNewswire) -16.67%
Mar-17-26 07:50AM	HCW Biologics Closes Exclusive Worldwide License for HCW11-006 - A High Potential Fusion Immunotherapeutic (GlobeNewswire) -6.33%
Mar-16-26 08:00AM	HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances (GlobeNewswire) +81.19%
Mar-02-26 08:00AM	HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter (GlobeNewswire)
Feb-17-26 09:50PM	HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules (GlobeNewswire) -7.54%
08:30AM	Loading…
Feb-13-26 08:30AM	HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune (GlobeNewswire) -21.23%
Nov-19-25 08:30AM	HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -17.01%
Nov-18-25 07:25AM	HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease (GlobeNewswire) -21.24%
Nov-14-25 04:44PM	HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results (GlobeNewswire) +20.48%
Nov-10-25 07:00AM	HCW Biologics Shares the Latest Data for its Second-Generation Immune Checkpoint Inhibitor Presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (GlobeNewswire)
Nov-07-25 07:00AM	HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting (GlobeNewswire) -9.04%
Oct-22-25 09:00AM	HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor "What This Means" Segment (GlobeNewswire)
Oct-16-25 09:25AM	HCW Biologics to Participate in the 2025 Maxim Growth Summit (GlobeNewswire) -7.37%
09:15AM	HCW Biologics' Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer (GlobeNewswire)
Sep-30-25 08:45AM	HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor "What This Means" Segment About its Proprietary T-Cell Engager Program (GlobeNewswire)
09:15AM	Loading…
Sep-18-25 09:15AM	HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing (GlobeNewswire) +5.34%
09:10AM	Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics (PR Newswire)
Sep-16-25 08:00AM	HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development (GlobeNewswire) -15.31%
Sep-09-25 08:00AM	HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program (GlobeNewswire) -6.82%
Aug-25-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +60.82%
08:00AM	HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market (GlobeNewswire)
Aug-18-25 02:44PM	HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
Jun-27-25 07:45AM	HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors (GlobeNewswire) +6.64%
Jun-26-25 07:55AM	HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements (GlobeNewswire) -5.17%
Jun-04-25 08:20AM	HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech (GlobeNewswire) -8.36%
May-15-25 06:14PM	HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results (GlobeNewswire) -6.92% +9.15%
May-13-25 08:01PM	HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules (GlobeNewswire) +92.90% -12.34%
08:30AM	HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization (GlobeNewswire)
Apr-01-25 04:35PM	HCW Biologics Announces 1-for-40 Reverse Stock Split (GlobeNewswire)
Mar-28-25 03:30PM	HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results (GlobeNewswire)
06:55AM	Loading…
Mar-06-25 06:55AM	HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements (GlobeNewswire)
Feb-03-25 07:15AM	HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial (GlobeNewswire) +128.58%
Jan-15-25 07:00AM	HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025 (GlobeNewswire)
Dec-23-24 08:10AM	HCW Biologics Inc. Received NASDAQ Staff Determination Letter (GlobeNewswire) -11.18%
Nov-20-24 01:55AM	HCW Biologics prices $6.9M registered direct offering at $1.03 per share (TipRanks) -13.89%
Nov-18-24 09:27PM	HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules (GlobeNewswire) +320.91% -11.29%
10:15AM	Why Is Penny Stock HCW Biologics Surging On Monday? (Benzinga)
07:00AM	HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate (GlobeNewswire)
Nov-14-24 04:40PM	HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Aug-23-24 04:30PM	HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction (GlobeNewswire) +11.64% -11.21%
Aug-14-24 04:35PM	HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) -13.62%
May-15-24 09:53PM	HCWB Stock Earnings: HCW Biologics Reported Results for Q1 2024 (InvestorPlace) -5.17%
04:39PM	HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Apr-01-24 10:53PM	HCWB Stock Earnings: HCW Biologics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -5.71%
04:10PM	HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights (GlobeNewswire)
Nov-14-23 07:00AM	HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights (GlobeNewswire) -17.73%
Nov-08-23 07:30AM	Investigator Sponsor of HCW Biologics' Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting (GlobeNewswire)
Nov-01-23 07:30AM	Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting (GlobeNewswire) -5.36%
Sep-16-23 11:00AM	Insider Buying: CFO Rebecca Byam Acquires 5,000 Shares of HCW Biologics Inc (GuruFocus.com)
Sep-14-23 01:27PM	Insider Buying: CFO Rebecca Byam Acquires 10,000 Shares of HCW Biologics Inc (GuruFocus.com) +5.45%
Sep-09-23 01:00PM	Insider Buying: CFO Rebecca Byam Acquires 10,000 Shares of HCW Biologics Inc (GuruFocus.com)
Sep-06-23 07:30AM	HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 13, 2023 (GlobeNewswire)
Aug-11-23 07:01AM	Daily Vickers Top Insider Picks for 08/11/2023 (Argus Research)
07:00AM	HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-10-23 06:24AM	Daily Vickers Top Insider Picks for 08/10/2023 (Argus Research)
Aug-09-23 06:26AM	Daily Vickers Top Insider Picks for 08/09/2023 (Argus Research)
Aug-08-23 06:28AM	Daily Vickers Top Insider Picks for 08/08/2023 (Argus Research)
Aug-07-23 06:35AM	Daily Vickers Top Insider Picks for 08/07/2023 (Argus Research)
Aug-04-23 07:14AM	Daily Vickers Top Insider Picks for 08/04/2023 (Argus Research) -8.26%
Aug-03-23 07:15AM	Daily Vickers Top Insider Picks for 08/03/2023 (Argus Research)
Aug-02-23 07:52AM	Daily Vickers Top Insider Picks for 08/02/2023 (Argus Research)
Aug-01-23 06:51AM	Daily Vickers Top Insider Picks for 08/01/2023 (Argus Research)
Jul-31-23 06:44AM	Daily Vickers Top Insider Picks for 07/31/2023 (Argus Research)
Jul-28-23 07:58AM	Daily Vickers Top Insider Picks for 07/28/2023 (Argus Research)
Jul-27-23 07:10AM	Daily Vickers Top Insider Picks for 07/27/2023 (Argus Research)
Jul-26-23 01:12PM	Daily Vickers Top Insider Picks for 07/26/2023 (Argus Research)
Jul-25-23 07:16AM	Daily Vickers Top Insider Picks for 07/25/2023 (Argus Research)
Jul-24-23 07:12AM	Daily Vickers Top Insider Picks for 07/24/2023 (Argus Research)
Jul-21-23 07:23AM	Daily Vickers Top Insider Picks for 07/21/2023 (Argus Research)
Jul-20-23 06:55AM	Daily Vickers Top Insider Picks for 07/20/2023 (Argus Research)
Jul-19-23 07:10AM	Daily Vickers Top Insider Picks for 07/19/2023 (Argus Research)
Jul-18-23 06:53AM	Daily Vickers Top Insider Picks for 07/18/2023 (Argus Research)
Jul-17-23 07:10AM	Daily Vickers Top Insider Picks for 07/17/2023 (Argus Research) +5.42%
Jul-14-23 06:50AM	Daily Vickers Top Insider Picks for 07/14/2023 (Argus Research) -8.23%
Jul-13-23 07:02AM	Daily Vickers Top Insider Picks for 07/13/2023 (Argus Research) +6.45%
Jul-12-23 07:22AM	Daily Vickers Top Insider Picks for 07/12/2023 (Argus Research)
Jul-11-23 06:08AM	Daily Vickers Top Insider Picks for 07/11/2023 (Argus Research)
Jul-10-23 06:56AM	Daily Vickers Top Insider Picks for 07/10/2023 (Argus Research)
Jul-07-23 06:28AM	The past year for HCW Biologics (NASDAQ:HCWB) investors has not been profitable (Simply Wall St.)
Jul-05-23 06:46AM	Daily Vickers Top Insider Picks for 07/05/2023 (Argus Research)
Jul-03-23 06:50AM	Daily Vickers Top Insider Picks for 07/03/2023 (Argus Research)
Jun-30-23 06:52AM	Daily Vickers Top Insider Picks for 06/30/2023 (Argus Research)
Jun-29-23 06:49AM	Daily Vickers Top Insider Picks for 06/29/2023 (Argus Research)
Jun-28-23 06:58AM	Daily Vickers Top Insider Picks for 06/28/2023 (Argus Research)
Jun-27-23 06:46AM	Daily Vickers Top Insider Picks for 06/27/2023 (Argus Research)
Jun-26-23 06:41AM	Daily Vickers Top Insider Picks for 06/26/2023 (Argus Research) -5.22%
Jun-23-23 09:24AM	Daily Vickers Top Insider Picks for 06/23/2023 (Argus Research) +12.75%
Jun-22-23 07:05AM	Daily Vickers Top Insider Picks for 06/22/2023 (Argus Research)
Jun-21-23 07:05AM	Daily Vickers Top Insider Picks for 06/21/2023 (Argus Research)
Jun-20-23 06:35AM	Daily Vickers Top Insider Picks for 06/20/2023 (Argus Research)
Jun-15-23 06:38AM	Daily Vickers Top Insider Picks for 06/15/2023 (Argus Research)
Jun-14-23 07:30AM	HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders (GlobeNewswire)
06:39AM	Daily Vickers Top Insider Picks for 06/14/2023 (Argus Research)
Jun-13-23 06:37AM	Daily Vickers Top Insider Picks for 06/13/2023 (Argus Research)
Jun-12-23 06:47AM	Daily Vickers Top Insider Picks for 06/12/2023 (Argus Research)
Jun-09-23 06:34AM	Daily Vickers Top Insider Picks for 06/09/2023 (Argus Research) -6.05%
May-10-23 06:13AM	HCW Biologics First Quarter 2023 Earnings: US$0.14 loss per share (vs US$0.057 loss in 1Q 2022) (Simply Wall St.)
May-09-23 07:15AM	HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights (GlobeNewswire)
Apr-27-23 07:40AM	HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan (GlobeNewswire)
Apr-13-23 07:15AM	HCW Biologics Poster Presentation at AACR Annual Meeting 2023 (GlobeNewswire)

HCW Biologics Inc. is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases. The firm considers age-related low-grade chronic inflammation as a contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune diseases. The company was founded by Hing C. Wong on April 2, 2018 and is headquartered in Miramar, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wong Hing C	Chief Executive Officer	May 16 '25	Buy	7.45	8,054	60,002	501,911	May 20 04:35 PM
Winer Gary M	Director	May 16 '25	Buy	7.45	1,342	9,998	4,075	May 20 04:35 PM
GARRETT SCOTT T	Director	May 16 '25	Buy	7.45	13,423	100,001	25,505	May 20 04:34 PM
Winer Gary M	Director	May 08 '25	Buy	26.00	2,308	60,008	2,733	May 09 05:33 PM
Wong Hing C	Chief Executive Officer	May 08 '25	Buy	26.00	92,500	2,405,000	493,857	May 09 05:32 PM
GARRETT SCOTT T	Director	May 08 '25	Buy	26.00	5,385	140,010	12,082	May 09 05:31 PM
Byam Rebecca	Chief Financial Officer	May 08 '25	Buy	26.00	8,462	220,012	43,010	May 09 05:30 PM
Flowers Lee	SVP of Business Development	May 08 '25	Buy	26.00	962	25,012	5,720	May 09 05:29 PM
Greene Rick S.	Director	May 08 '25	Buy	26.00	962	25,012	2,066	May 09 05:28 PM

LNSR

LENSAR Inc

HCWB

HCW Biologics Inc

Upgrade your Finviz experience